Scientists have developed a simple DNA blood test
that can predict how well patients with breast cancer will respond to treatment.
More than 2 million people globally each year are diagnosed with the disease,
which is the world’s most prevalent cancer.
Although treatments have improved in recent decades, it is not easy to know which ones will work best for which patients.
Now researchers have designed a #liquid #biopsy that tells doctors how likely a patient is to respond to a specific treatment -- even before it begins.
The test has the potential to be gamechanging because it means patients could be offered alternative options, and avoid treatments that won’t help them, boosting their chances of beating the disease.
The test, developed by a team at the Institute of Cancer Research, London (ICR),
analyses #circulating #tumour #DNA (ctDNA), which is released into the blood of patients by cancer cells.
Researchers measured these microscopic levels of cancer DNA in blood samples from 167 patients.
The test was trialled before treatment began and again four weeks later, after a single treatment cycle.
There was a strong association between low levels of ctDNA at the start of treatment, and treatment response, according to the team.
A similar association was seen with the results taken at four weeks.
https://www.theguardian.com/science/2026/jan/18/simple-blood-test-can-predict-which-breast-cancer-treatment-will-work-best-study-finds?CMP=Share_iOSApp_Other